Taken together, conjugation of RBCEVs with anti‐CD33 antibody significantly promotes the delivery of miR‐125b ASO‐loaded RBCEVs thus enhancing the suppression of leukaemia in patient‐derived AML xenografts. The gene discussed is CD33; the disease is leukemia.